SURMOUNT-2: Tirzepatide for Weight Loss in People with Type 2 Diabetes
The SURMOUNT-2 trial studied tirzepatide's weight loss effects specifically in patients with type 2 diabetes and obesity. Here are the results.
SURMOUNT-2 addressed a critical question: how effective is tirzepatide for weight loss in people who have both type 2 diabetes and obesity?
Study Design
- Participants: 938 adults with BMI ≥27 and type 2 diabetes
- Duration: 72 weeks
- Doses: Tirzepatide 10 mg and 15 mg vs. placebo
- Background therapy: Metformin ± other oral diabetes medications
Key Results
Weight Loss
- Tirzepatide 10 mg: -12.8% body weight
- Tirzepatide 15 mg: -14.7% body weight
- Placebo: -3.2% body weight
HbA1c Reduction
- Tirzepatide 10 mg: -2.1%
- Tirzepatide 15 mg: -2.1%
- Placebo: -0.5%
Weight Loss Milestones (15 mg)
- ≥5% weight loss: 83%
- ≥10% weight loss: 60%
- ≥15% weight loss: 40%
Why This Trial Matters
Weight loss is typically more difficult in people with type 2 diabetes due to:
- Insulin resistance promoting fat storage
- Some diabetes medications causing weight gain
- Metabolic adaptations that resist weight loss
SURMOUNT-2 showed that tirzepatide overcomes these barriers, producing meaningful weight loss even in this harder-to-treat population. While the weight loss was somewhat less than in SURMOUNT-1 (which excluded diabetes patients), it was still far superior to any previous anti-obesity medication studied in diabetic populations.
Dual Benefits
A unique advantage of tirzepatide in this population is the simultaneous improvement in both:
- Body weight → reduces obesity-related complications
- Blood sugar → improves diabetes control, potentially leading to remission
This dual benefit makes tirzepatide particularly valuable for the estimated 85% of people with type 2 diabetes who also have overweight or obesity.